

Kurztitel	Phase	Indikation	Hauptprüfer
ACE-536-MDS-002 (COMMANDS)	3	A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR	Götze, Katharina
AIO-KRK-0117 / Elderly	2	Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for elderly or frail elderly patients with metastatic colorectal cancer	Lorenzen, Sylvie
AIO-STO-0417 (Moonlight)	2	Modified FOLFOX plus/minus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction	Lorenzen, Sylvie
Alternative-C	2	A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Irinotecan	Heidegger, Simon
AMG 199 - 20180290	1	A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects	Lorenzen, Sylvie
AMG910 - 20180292	1	A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 910 in Subjects	Lorenzen, Sylvie
AMGEN NIS 20180293	keine Phase	A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Gastric Cancer - AMGEN 20180293	Lorenzen, Sylvie
AMLSG 29-18	3	A phase 3, multicenter, double-blind, randomized, placebo-controlled study of AG-120 or AG-221 in combination with induction therapy and consolidation therapy for relapsed and refractory acute myeloid leukemia	Götze, Katharina
AMLSG 30-18	3	Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Incomplete Remission	Götze, Katharina
AMLSG BIO	keine Phase	Registry Study on Biological Disease Profile and Clinical Outcome in AML and Related Neoplasms, and Acute Leukemias of Ambiguous Lineage	Götze, Katharina
Apollo	3	A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycline-based chemotherapy in relapsed and refractory acute promyelocytic leukemia	Götze, Katharina
CA209-77T	3	A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection	Schneller, Folker
CA-4948-102	1	A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Advanced Solid Tumors	Götze, Katharina
CC-92480-MM-002	1 - 2	A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Patients with Metastatic Mucosal Melanoma	Bassermann, Florian
CLL2-BZAG	2	A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab), Heidegger, Simon	Heidegger, Simon
COSS Register	keine Phase	Register für Osteosarkom	Götze, Katharina
CP-MGD006-001	1	A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed and Refractory Acute Myeloid Leukemia	Götze, Katharina
DESTINY-Gastric03	1 - 2	A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Anti-tumor Activity of Trastuzumab Derivat	Lorenzen, Sylvie
DSMM XV	2	Pomalidomide, ixazomib, and dexamethasone (PId) with or without intensification by cyclophosphamide (PICd): A phase II study in relapsed or refractory multiple myeloma	Bassermann, Florian
EORTC 1203 (Innovation)	2	Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive gastric and gastroesophageal junction Type II/III adenocarcinoma: The INNOVATION trial	Lorenzen, Sylvie
EORTC Vestige	2	Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled trial	Lorenzen, Sylvie
EWALL-BOLD	2	Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential imatinib and rituximab	Schneller, Folker
Fascination	2	Frontline ASCIMINIB COMBINATION IN CHRONIC PHASE CML (nur noch in Kohorte mit Nilotinib offen)	Herhaus, Peter
FIRE-6 Avelumab Study	2	Avelumab Added to FOLFIRI plus Cetuximab Followed by Avelumab Maintenance in Patients with Previously Untreated RAS/BRAF Wild-Type Metastatic Colorectal Cancer	Lorenzen, Sylvie
FLOT9/HIPEC	3	Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal Junction Type II/III adenocarcinoma	Lorenzen, Sylvie
GAZAI	2	Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Rituximab	Heidegger, Simon
GEM3PSCA-01	1	A Multicenter, Open-label, Dose-escalating, Phase I Trial with GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients with Progressive Diffuse Large B-cell Lymphoma	Lorenzen, Sylvie
GMALL 08/2013	TOP	Therapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter Akuter Lymphatischer Leukämie (ALL) oder Lymphoblastischem Lymphom (LBL) durch individuelle Therapieanpassung	Schneller, Folker
GMALL Register	keine Phase	Biomaterialsammmlung und prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen	Schneller, Folker
HD 21	3	Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrE	Herhaus, Peter
Ideal	2	A single-arm phase II multicenter study of IDH2 (AG 221) inhibitor in patients with IDH2 mutated myelodysplastic syndrome	Götze, Katharina
IDH2-Post-Allo-Trial	3	Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS following allogeneic blood stem cell transplantation	Verbeek, Mareike
IDUNN / MC-MSC.1/aGvHD	3	A Randomised, Open-label, Multicentre, Phase 3 Trial of First-line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Patients with Acute Graft-versus-Host Disease	Verbeek, Mareike
Imbruvic®/R-CHOP-Trial	2	Ibrutinib (Imbruvic®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma	Herhaus, Peter
INCB 391110-309 / GRAVITAS-309	3	A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-versus-Host Disease	Verbeek, Mareike
IOV-COM-202	2	A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors	Krackhardt, Angela
		A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment	Herhaus, Peter
KRT-232-101 Part B	3	Refractory to Janus Kinase (JAK) Inhibitor Treatment	Herhaus, Peter
M15-954	3	Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with High-Risk Acute Myeloid Leukemia	Götze, Katharina
M16-191 Transform1	3	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis (TR)	Herhaus, Peter
M20-178 Transform2	3	A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Myelofibrosis	Herhaus, Peter
Matterhorn	3	A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric Cancer	Lorenzen, Sylvie
MDS-Register	keine Phase	Register	Götze, Katharina
Mirati 516-005 / Sapphire	3	A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer	Schneller, Folker
MK-3475-811	3	A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo in Patients with Metastatic Breast Cancer	Lorenzen, Sylvie
MK7902-015	3	A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Chemotherapy in Patients with Metastatic Hepatocellular Carcinoma	Lorenzen, Sylvie
MOR208C310 - frontMIND	3	A Phase 3, multicenter, randomized, double-blind, placebocontrolled trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP in patients with relapsed and refractory multiple myeloma	Heidegger, Simon
MPN-Register	keine Phase	Register	Herhaus, Peter
NAPOLEON-Register	keine Phase	Register Akute Promyelozyten-Leukämie (APL)	Götze, Katharina
NAUT	2	Multicenter prospective trial after first unsuccessful Treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistent complete remission	Herhaus, Peter
Paloma	2	Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies before allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia: The PALOMA trial	Götze, Katharina
		I: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ).	Lorenzen, Sylvie
RACE	3	Junction (GEJ).	Lorenzen, Sylvie
RENAISSANCE / FLOT 5	3	Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or gastroesophageal junction	Lorenzen, Sylvie
TEAM	2	Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach	Götze, Katharina
The Phase III RAMIRIS Study	2 - 3	Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction	Lorenzen, Sylvie
TRACE	3	Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, randomized, controlled trial	Verbeek, Mareike
TUD-PEMAZA-068	2	MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse	Götze, Katharina